References
- ADAIR JR, BAKER TS, BEBBINGTON CR, BEELEY NRA, EMTAGE JS, KING DJ, LAWSON ADG, MILLICAN TA, MOUNTAIN A, OWNES RJ, YARRANTON GT: Engineering monoclonal antibody B72.3 for cancer therapy. In: Protein Engineering of Antibody Molecules for Prophylactic and Therapeutic Applications in Man. (1992) Clark MR (Ed) In Press.
- TAKASHLNA K, KITAMURA K, YAMAGUCHI T, NOGUCHI AKINORI, NOGUCHI AKIRA, TSURUMI H, TAKAHASHI T: Comparative pharmacokinetic properties of murine monoclonal antibody A7 modified with neocarzinostatin, dextran and polyethylene glycol. Jpn. J. Cancer Res. (1991) 82:1145–1150.
- FRANCIS GE, DELGADO C, FISHER D: PEG modified proteins. In: Pharmaceutical Biotechnology. Borchardt RT (Ed), Volume 3: Stability of protein pharmaceuticals: In vivo pathways of degra- dation and strategies for stabilization. (1992) Ahern TJ, Manning M (Eds) Plenum Press, NY, In Press.
- ISHIGURO M, Immo S, HIRAMA H: Modelling study of the structure of the macromolecularantitumour antibiotic neocarzinostatin. Origin of the stabilization of the chromophore. J. Med. Chem. (1991) 34:2366–2373